EA202090891A1 - Молекулы антител против cd138 и их применение - Google Patents

Молекулы антител против cd138 и их применение

Info

Publication number
EA202090891A1
EA202090891A1 EA202090891A EA202090891A EA202090891A1 EA 202090891 A1 EA202090891 A1 EA 202090891A1 EA 202090891 A EA202090891 A EA 202090891A EA 202090891 A EA202090891 A EA 202090891A EA 202090891 A1 EA202090891 A1 EA 202090891A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody molecules
application
molecules against
treat
prevent
Prior art date
Application number
EA202090891A
Other languages
English (en)
Inventor
Бхарат Чаганти
Боопати Рамакришнан
Хеди Адари-Холл
Картик Висванатхан
Джеймс Р. Майетт
Закари Шрайвер
Original Assignee
Вистерра, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вистерра, Инк. filed Critical Вистерра, Инк.
Priority claimed from PCT/US2018/053989 external-priority patent/WO2019070726A1/en
Publication of EA202090891A1 publication Critical patent/EA202090891A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Настоящее изобретение относится к молекулам антител, специфически связывающимся с CD138. Молекулы антител можно применять для лечения, профилактики и/или диагностики нарушений, таких как множественная миелома.
EA202090891A 2018-08-31 2018-10-02 Молекулы антител против cd138 и их применение EA202090891A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725880P 2018-08-31 2018-08-31
PCT/US2018/053989 WO2019070726A1 (en) 2017-10-02 2018-10-02 CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF

Publications (1)

Publication Number Publication Date
EA202090891A1 true EA202090891A1 (ru) 2020-08-27

Family

ID=72235060

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090891A EA202090891A1 (ru) 2018-08-31 2018-10-02 Молекулы антител против cd138 и их применение

Country Status (1)

Country Link
EA (1) EA202090891A1 (ru)

Similar Documents

Publication Publication Date Title
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
EA201691765A1 (ru) Молекулы антител против lag-3 и их применения
EA201791712A1 (ru) Антитела к транстиретину
EA201990033A1 (ru) Вариантные аденоассоциированные вирусы и способы их применения
EA201891909A1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201791711A1 (ru) Антитела к транстиретину
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
EA201791710A1 (ru) Антитела к транстиретину
EA201992091A1 (ru) Анти-c5 антитела и их применение
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
MX2020003041A (es) Anticuerpos anti-transtiretina.
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
MX2022008659A (es) Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA202191471A1 (ru) Противовоспалительные полипептиды
EA202090891A1 (ru) Молекулы антител против cd138 и их применение